Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Triple Negative Breast Neoplasms 2Neuroblastoma 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Neoplasms 1Melanoma 1Lung Neoplasms 1Ganglioneuroblastoma 1Endometrial Neoplasms 1Carcinosarcoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Hepatocellular 1Adenoma, Islet Cell 1Adenocarcinoma 1

Interventions

Oxaliplatin 10pembrolizumab 8Fluorouracil 8Leucovorin 7Paclitaxel 5Gemcitabine 5Docetaxel 5Capecitabine 5Cyclophosphamide 4Blood Specimen Collection 4zolbetuximab 3fludarabine 3darolutamide 3cemiplimab 3Trastuzumab 3Taxes 3Ramucirumab 3Radiotherapy 3Radiosurgery 3Irinotecan 3trastuzumab deruxtecan 2enzalutamide 2durvalumab 2Standard of Care 2Nivolumab 2Folfox protocol 2Dexamethasone 2Cisplatin 2130-nm albumin-bound paclitaxel 2tucatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Adenocarcinoma × Colony-Stimulating Factors × Clear all
NCT05101356 2024-05-21

A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma

University of California, Davis

Phase 1/2 Recruiting
77 enrolled
Tumor-Agnostic

Adenocarcinoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡